 |
Shin Tae-hyun, CEO of Inventera, Speaking at a Corporate Briefing (Photo: Inventera) |
[Alpha Biz= Ellie Kim] Inventera announced on the 27th that it has registered a patent for its proprietary nanostructure platform, “Invinity,” with the Australian Patent Office.
The patent, titled “Nanostructures Excreted via the Kidneys Without Being Phagocytosed or Metabolically Degraded by Macrophages After In Vivo Administration,” covers core source technology behind the Invinity platform. The technology is designed to enable nanostructures to remain stable in the body without being readily cleared by immune cells, before being safely excreted through the kidneys.
Inventera developed the Invinity platform to address key limitations in nanomedicine, including protein corona formation, low dispersion stability, and immune cell uptake. Leveraging this platform, the company is prioritizing the development of disease-specific nano-MRI contrast agents, while also exploring expansion into therapeutics such as antibody-drug conjugates (ADCs).
The company noted that the Australian patent registration is meaningful as it reinforces its efforts to secure core technology rights across major global markets. Inventera previously obtained U.S. patents for its nano-MRI contrast agent pipeline, further strengthening its global intellectual property portfolio.
Australia is considered a strategically important market with strong alignment to advanced pharmaceutical markets such as the United States and Europe in terms of regulation and clinical development. Inventera expects the latest patent to support future global commercialization and technology licensing strategies.
Inventera is building a strategic global patent portfolio centered on the Invinity platform and its key pipelines, filing patents across major jurisdictions, securing freedom-to-operate (FTO), and pursuing lifecycle management strategies such as patent term extensions.
The company is developing nano-MRI contrast agents using biocompatible iron (Fe) as a payload, offering high-performance imaging without the use of gadolinium. Conventional MRI contrast agents are typically gadolinium-based, raising concerns over accumulation in the body and long-term safety.
Its lead pipeline, “INV-002,” a nano-MRI contrast agent for musculoskeletal diseases, is in the final stage of Phase 3 clinical trials in Korea, with regulatory submission underway. The candidate also received U.S. FDA approval for a Phase 2b Investigational New Drug (IND) application at the end of 2024.
A follow-up pipeline, “INV-001,” targets lymphatic diseases and is currently in Phase 2a clinical trials in Korea, with a U.S. Phase 2 IND approved in February. Another candidate, “INV-003,” for pancreatobiliary diseases, has completed preclinical efficacy and safety studies, with plans to file for Phase 1 IND approval and initiate trials within the year.
Alphabiz Ellie Kim 인턴기자(press@alphabiz.co.kr)
